Black Rock Inc. Medicinova Inc Transaction History

Black Rock Inc.

$4.23 Trillion
Q1 2024

A detailed history of Black Rock Inc. transactions in Medicinova Inc stock. As of the latest transaction made, Black Rock Inc. holds 695,420 shares of MNOV stock, worth $973,587. This represents 0.0% of its overall portfolio holdings.

Number of Shares

695,420

Previous 699,642 0.6%

Holding current value

$973,587

Previous $1.05 Million 3.91%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$1.28 - $1.65 $5,404 - $6,966	-4,222 Reduced 0.6%	695,420 $1.01 Million
Q4 2023 Feb 13, 2024	BUY	$1.38 - $2.06 $5,582 - $8,332	4,045 Added 0.58%	699,642 $1.05 Million
Q3 2023 Nov 13, 2023	SELL	$2.01 - $2.6 $71,901 - $93,007	-35,772 Reduced 4.89%	695,597 $1.45 Million
Q2 2023 Aug 11, 2023	BUY	$2.09 - $2.43 $34,459 - $40,065	16,488 Added 2.31%	731,369 $1.68 Million
Q1 2023 May 12, 2023	BUY	$1.95 - $2.54 $6,043 - $7,871	3,099 Added 0.44%	714,881 $1.54 Million

Q4 2022 Feb 13, 2023	BUY	$1.97 - $2.66 $2,220 - $2,997	1,127 Added 0.16%	711,782 $1.46 Million
Q3 2022 Nov 14, 2022	SELL	$2.1 - $2.6 $9,886 - $12,240	-4,708 Reduced 0.66%	710,655 $1.54 Million
Q2 2022 Aug 12, 2022	SELL	$2.31 - $3.14 $14,994 - $20,381	-6,491 Reduced 0.9%	715,363 $1.81 Million
Q1 2022 May 12, 2022	SELL	$2.19 - $2.81 $21,983 - $28,206	-10,038 Reduced 1.37%	721,854 $1.93 Million
Q4 2021 Feb 10, 2022	SELL	$2.61 - $4.42 $1.08 Million - $1.83 Million	-414,078 Reduced 36.13%	731,892 $1.96 Million
Q3 2021 Nov 09, 2021	BUY	$3.4 - $4.24 $61,363 - $76,523	18,048 Added 1.6%	1,145,970 $4.34 Million
Q2 2021 Aug 11, 2021	BUY	$3.76 - $5.14 $4.24 Million - $5.8 Million	1,127,922 New	1,127,922 $4.79 Million

Others Institutions Holding MNOV

# of Institutions

Shares Held

4.58M

Call Options Held

12.5K

Put Options Held

View Full List

About MEDICINOVA INC

Ticker MNOV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,046,200
Market Cap $68.7M
Description
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and ...

More about MNOV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account